1. Home
  2. TCRX vs UCL Comparison

TCRX vs UCL Comparison

Compare TCRX & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

SELL

Current Price

$0.14

Market Cap

11.8M

Sector

Health Care

ML Signal

SELL

Logo uCloudlink Group Inc.

UCL

uCloudlink Group Inc.

SELL

Current Price

$0.22

Market Cap

10.6M

ML Signal

SELL

Company Overview

Basic Information
Metric
TCRX
UCL
Founded
2018
2014
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
10.6M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
TCRX
UCL
Price
$0.14
$0.22
Analyst Decision
Hold
Analyst Count
5
0
Target Price
★ $1.00
N/A
AVG Volume (30 Days)
420.2K
★ 444.2K
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 12.28
N/A
EPS
N/A
★ N/A
Revenue
★ $10,325,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$13.96
P/E Ratio
★ N/A
$13.72
Revenue Growth
★ 266.65
N/A
52 Week Low
$0.14
$0.15
52 Week High
$1.47
$2.38

Technical Indicators

Market Signals
Indicator
TCRX
UCL
Relative Strength Index (RSI) 31.39 44.25
Support Level N/A $0.21
Resistance Level $0.21 $0.25
Average True Range (ATR) 0.02 0.03
MACD 0.00 0.00
Stochastic Oscillator 8.07 55.93

Price Performance

Historical Comparison
TCRX
UCL

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.

Share on Social Networks: